CN115089607A - Medicament for treating Chinese cobra toxin poisoning and preparation method thereof - Google Patents
Medicament for treating Chinese cobra toxin poisoning and preparation method thereof Download PDFInfo
- Publication number
- CN115089607A CN115089607A CN202111256967.2A CN202111256967A CN115089607A CN 115089607 A CN115089607 A CN 115089607A CN 202111256967 A CN202111256967 A CN 202111256967A CN 115089607 A CN115089607 A CN 115089607A
- Authority
- CN
- China
- Prior art keywords
- mice
- prp
- group
- skin
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000272144 Naja atra Species 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000003053 toxin Substances 0.000 title claims abstract description 15
- 231100000765 toxin Toxicity 0.000 title claims abstract description 15
- 231100000572 poisoning Toxicity 0.000 title claims abstract description 13
- 230000000607 poisoning effect Effects 0.000 title claims abstract description 13
- 231100000611 venom Toxicity 0.000 claims abstract description 12
- 239000002435 venom Substances 0.000 claims abstract description 10
- 210000001048 venom Anatomy 0.000 claims abstract description 10
- 239000003102 growth factor Substances 0.000 claims abstract description 6
- 230000035876 healing Effects 0.000 claims abstract description 6
- 230000035987 intoxication Effects 0.000 claims abstract description 6
- 231100000566 intoxication Toxicity 0.000 claims abstract description 6
- 238000002347 injection Methods 0.000 claims abstract description 5
- 239000007924 injection Substances 0.000 claims abstract description 5
- 241000699670 Mus sp. Species 0.000 claims description 39
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 230000001338 necrotic effect Effects 0.000 claims description 8
- 206010040893 Skin necrosis Diseases 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 101710112752 Cytotoxin Proteins 0.000 claims description 3
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 239000002619 cytotoxin Substances 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 230000002107 myocardial effect Effects 0.000 claims description 3
- 239000013642 negative control Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 210000003462 vein Anatomy 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 abstract description 4
- 231100000019 skin ulcer Toxicity 0.000 abstract description 4
- 102000008186 Collagen Human genes 0.000 abstract description 3
- 108010035532 Collagen Proteins 0.000 abstract description 3
- 210000004204 blood vessel Anatomy 0.000 abstract description 3
- 229920001436 collagen Polymers 0.000 abstract description 3
- 239000000835 fiber Substances 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 210000002919 epithelial cell Anatomy 0.000 abstract description 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 208000005374 Poisoning Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 5
- 241000270295 Serpentes Species 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- 239000002642 cobra venom Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000004920 epithelial cell of skin Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000037972 tropical disease Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Abstract
The present invention provides a medicament for treating chinese cobra toxin intoxication comprising prp; the preparation method of the medicament for treating the poisoning of the Chinese cobra toxins comprises the following steps of S1 and model making; s2, preparing prp; s3, venom injection; s4, recording poisoning; s5, treatment; s6, observation; the invention has the beneficial effects that: the prp is prepared into a medicament, and various growth factors are utilized to stimulate the growth of epithelial cells and blood vessels of the skin and the generation of collagen fibers, so that the healing of skin ulcer is promoted; meanwhile, the product can be stored at 0 ℃, the storage requirement is easy to achieve, and the product is convenient to carry and transport.
Description
Technical Field
The invention relates to the technical field of medical drugs, in particular to a medicament for treating Chinese cobra toxin poisoning and a preparation method thereof.
Background
Venomous snake bites are an overlooked tropical disease that causes considerable pain, disability and premature death to people in many countries and poor regions. More than 58 million people worldwide face the danger of encountering the poisonous snake, nearly 7400 people are bitten by the snake every day, and 220 men, women, old and young die. According to the report of WHO in 2019, about 450-540 million people are bitten by snakes every year, and 180-270 million people are bitten by vipers, so that 8.1-13.8 million people die, and 40 million people are left with lifelong disabilities. In most countries, the economic cost of treating venomous snake bites is prohibitive. Although about 68.5 million people live in snake-populated areas throughout the world, about 1.467 million people live in remote areas lacking premium medical services.
At present, the skin ulcer caused by cobra bite lacks obvious curative effect by the traditional method for treating the serum resisting cobra venom, the cold chain storage and transportation requirements are high, the cost is high, and the problem of on-site treatment of snake venom poisoning cannot be solved.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a medicament for treating Chinese cobra toxin poisoning and a preparation method thereof.
The invention solves the technical problems through the following technical means:
a medicament for treating Chinese cobra toxin intoxication comprises prp (platelet rich plasma).
In an improvement of the above technical solution, the prp contains concentrated platelets and growth factors, and the platelets in the prp are concentrated to more than five times of normal state.
The preparation method of the medicament for treating the poisoning of the Chinese cobra toxin comprises the following steps,
s1, model creation
Selecting 40 healthy km mice, dividing into four groups of 10 mice each;
s2, preparation of prp
3ml of venous blood of the volunteers is taken; centrifuging blood to obtain prp preparation, and storing at 0 deg.C;
s3 venom injection
Performing venom injection on km mice in each group, wherein the venom is obtained by mixing and dissolving Chinese cobra cytotoxin and deionized water;
s4 poisoning record
Seven days later, the skin of the km mice in each group is obviously necrotic, the skin necrosis area of the km mice is recorded, a sample is extracted for the detection of the myocardial enzyme, and the skin necrosis condition of the km mice is shown in figure 2;
s5, treatment
Cleaning the wound surfaces of the skin of all km mice in S4, removing necrotic tissues in a proper amount, coating prp gel on the wound of a first group of km mice and wrapping the wound with gauze, and coating ppp gel on the wound of a second group of km mice and wrapping the wound with gauze; the km mice of the third group were wound-cleaned with normal saline only and bandaged with a yarn block, used as a negative control group; the fourth group was used for blank control without further treatment.
S6, observation
The treatment was carried out for 14 days, and the skin healing of each km mouse was continuously recorded and sampled randomly for the detection of the cardiac enzymes.
As an improvement of the technical proposal, the blood is centrifuged for the second time in S2 to obtain prp, the first time is centrifuged for 5-20min at 100-.
The invention has the beneficial effects that: the prp is prepared into a medicament, and various growth factors are utilized to stimulate the growth of epithelial cells and blood vessels of the skin and the generation of collagen fibers, so that the healing of skin ulcer is promoted; meanwhile, the product can be stored at 0 ℃, the storage requirement is easy to achieve, and the product is convenient to carry and transport.
Drawings
FIG. 1 is a schematic flow chart of the pharmaceutical preparation for treating Chinese cobra toxin poisoning and the preparation method thereof according to the embodiment of the present invention;
FIG. 2 is a schematic representation of skin necrosis of km mice according to example 2 of the present invention;
FIG. 3 is a schematic diagram showing the skin of a first group of km mice healed on the fifth day according to example 2 of the present invention;
FIG. 4 is a schematic diagram of the skin of a second group of km mice as healed on the fourteenth day according to example 2 of the present invention.
FIG. 5 is a schematic representation of the skin of a third group of km mice as healed on day eighteenth according to example 2 of the present invention.
FIG. 6 is a schematic diagram of the skin of a fourth group of km mice as healed on the twentieth day as described in example 2 of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
It will be understood that when an element is referred to as being "secured to" another element, it can be directly on the other element or intervening elements may also be present. When an element is referred to as being "connected" to another element, it can be directly connected to the other element or intervening elements may also be present.
Example 1
The medicament for treating the poisoning by the Chinese cobra toxin comprises prp (platelet rich plasma), wherein the platelet rich plasma contains concentrated platelets and various growth factors; various growth factors are utilized to stimulate the growth of skin epithelial cells and blood vessels and the generation of collagen fibers, thereby promoting the healing of skin ulcer.
Example 2
As shown in fig. 1, the preparation method of the medicament for treating chinese cobra toxin intoxication comprises the following steps:
s1, model creation
Selecting 40 healthy km mice, dividing into four groups, and dividing each group into 10 mice;
s2, preparation of prp
3ml of venous blood collection is carried out on each volunteer;
centrifuging the blood for the second time to obtain platelet-rich plasma, namely prp, centrifuging the platelet-rich plasma for the first time at 200Xg of 100-;
s3 venom injection
Injecting venom into km mice in each group, wherein the venom is obtained by mixing and dissolving Chinese cobra cytotoxin and deionized water;
s4 poisoning record
Seven days later, the skin of the km mice in each group is obviously necrotic, the skin necrosis area of the km mice is recorded, a sample is extracted for the detection of the myocardial enzyme, and the skin necrosis condition of the km mice is shown in figure 2;
s5, treatment
Cleaning the wound surfaces of the skin of all km mice in S4, removing necrotic tissues in a proper amount, coating prp gel on the wound of a first group of km mice and wrapping the wound with gauze, and coating ppp (platelet poor plasma) gel on the wound of a second group of km mice and wrapping the wound with gauze; the km mice of the third group were wound-cleaned with normal saline only and bandaged with a yarn block, used as a negative control group; the fourth group was used for blank control without further treatment.
S6, observation
The treatment was carried out for 14 days, and the skin healing of each km mouse was continuously recorded and sampled for the detection of the cardiac enzymes.
FIG. 3 is a schematic diagram showing the skin of a first group of km mice healed on the fifth day according to example 2 of the present invention;
FIG. 4 is a schematic diagram of the skin of a second group of km mice as healed on the fourteenth day according to example 2 of the present invention.
FIG. 5 is a schematic representation of the skin of a third group of km mice as healed on day eighteenth according to example 2 of the present invention.
FIG. 6 is a schematic diagram of the skin of a fourth group of km mice as healed on the twentieth day as described in example 2 of the present invention.
Observation indexes are as follows:
1. local necrosis condition (necrotic area).
2. And (3) testing cardiac myozymes (the specific items are aspartate Aminotransferase (AST), phosphokinase (CK), Myoglobin (MYO), Lactate Dehydrogenase (LDH) and troponin I (aTnI).
3. Histopathological examination (normal skin muscle tissue and local necrotic skin muscle tissue).
It is noted that, in this document, relational terms such as first and second, and the like, if any, are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising an … …" does not exclude the presence of other identical elements in the process, method, article, or apparatus that comprises the element.
The above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (4)
1. A medicament for treating chinese cobra toxin intoxication characterized by: including prp.
2. The agent for treating chinese cobra toxin intoxication according to claim 1, wherein: the prp contains concentrated platelets and growth factors, and the platelets in the prp are concentrated to more than five times of normal state.
3. The preparation method of the medicament for treating the poisoning of the Chinese cobra toxin is characterized by comprising the following steps: comprises the following steps of (a) carrying out,
s1, model creation
Selecting 40 healthy km mice, dividing into four groups, and dividing each group into 10 mice;
s2, preparation of prp
3ml of blood is collected from veins of each volunteer; centrifuging blood to obtain prp preparation, and storing at 0 deg.C;
s3 venom injection
Injecting venom into km mice in each group, wherein the venom is obtained by mixing and dissolving Chinese cobra cytotoxin and deionized water;
s4 poisoning record
Seven days later, the skin of the km mice in each group is obviously necrotic, the skin necrosis area of the km mice is recorded, a sample is extracted for the detection of the myocardial enzyme, and the skin necrosis condition of the km mice is shown in figure 2;
s5, treatment
Cleaning the wound surfaces of the skin of all km mice in S4, removing necrotic tissues in a proper amount, coating prp gel on the wound of a first group of km mice and wrapping the wound with gauze, and coating ppp gel on the wound of a second group of km mice and wrapping the wound with gauze; the km mice of the third group were wound-cleaned with normal saline only and bandaged with a gauze piece to serve as a negative control group; the fourth group was used for blank control without further treatment.
S6, observation
The treatment was carried out for 14 days, and the skin healing of each km mouse was continuously recorded and sampled for the detection of the cardiac enzymes.
4. The agent for treating chinese cobra toxin intoxication according to claim 3 and the preparation method thereof, wherein: and S2, centrifuging the blood for the second time to obtain prp, centrifuging the blood for the first time at 200Xg and 100-.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111256967.2A CN115089607A (en) | 2021-10-27 | 2021-10-27 | Medicament for treating Chinese cobra toxin poisoning and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111256967.2A CN115089607A (en) | 2021-10-27 | 2021-10-27 | Medicament for treating Chinese cobra toxin poisoning and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115089607A true CN115089607A (en) | 2022-09-23 |
Family
ID=83287466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111256967.2A Pending CN115089607A (en) | 2021-10-27 | 2021-10-27 | Medicament for treating Chinese cobra toxin poisoning and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115089607A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120230968A1 (en) * | 2011-03-09 | 2012-09-13 | Worden Sr Charles E | Wound healant system and methods of use |
| WO2020032903A1 (en) * | 2018-08-10 | 2020-02-13 | T.C. Istanbul Medipol Universitesi | The use of platelet enhanced axolotl plasm in the treatment of wounds and burns |
-
2021
- 2021-10-27 CN CN202111256967.2A patent/CN115089607A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120230968A1 (en) * | 2011-03-09 | 2012-09-13 | Worden Sr Charles E | Wound healant system and methods of use |
| WO2020032903A1 (en) * | 2018-08-10 | 2020-02-13 | T.C. Istanbul Medipol Universitesi | The use of platelet enhanced axolotl plasm in the treatment of wounds and burns |
Non-Patent Citations (4)
| Title |
|---|
| 何雄等: "金黄散治疗眼镜蛇咬伤临床观察", 实用医技杂志, vol. 15, no. 20, 20 July 2008 (2008-07-20), pages 2643 - 2644 * |
| 刘思婧等: "富含血小板血浆修复小鼠皮肤组织缺损创面的实验研究", 天津医药, vol. 48, no. 6, 31 December 2020 (2020-12-31), pages 522 - 526 * |
| 张志文等: "富血小板血浆与贫血小板血浆治疗中华眼镜蛇细胞 毒素致小鼠皮肤溃疡的效果比较", 蛇志, vol. 35, no. 1, 31 January 2023 (2023-01-31), pages 4 - 8 * |
| 梁林青等: "自体富血小板凝胶治疗糖尿病皮肤慢性难愈合创面的临床疗效", 临床合理用药杂志, vol. 13, no. 4, 25 April 2020 (2020-04-25), pages 16 - 18 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KNAPP et al. | Injectable collagen for soft tissue augmentation | |
| Tuveri et al. | NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis | |
| Samudra et al. | Combination of the stromal vascular fraction and platelet-rich plasma accelerates the wound healing process: pre-clinical study in a Sprague-Dawley rat model | |
| WO1986002095A1 (en) | Process for the preparation of cellulose film, cellulose film produced thereby, artificial skin graft and its use | |
| Reksodiputro et al. | PRFM enhance wound healing process in skin graft | |
| CN113462632A (en) | Bitter gourd exosome, extraction method and application in preparation of medicine for treating burns and scalds | |
| Kim et al. | Early intervention with highly condensed adipose-derived stem cells for complicated wounds following filler injections | |
| CN109700998A (en) | A kind of compound skin injury regeneration renovation agent and preparation method thereof | |
| CN115089607A (en) | Medicament for treating Chinese cobra toxin poisoning and preparation method thereof | |
| CN113274410A (en) | Application of exosome hydrogel complex in preparation of medicine for repairing skin scar | |
| CN105288718A (en) | Surgical operation suture and preparation method thereof | |
| CN110731969A (en) | Preparation of mesenchymal stem cells and application of mesenchymal stem cells in preparation of pain medicines | |
| Kyriakidis et al. | Chronic leg ulcers: are tissue engineering and biomaterials science the solution? | |
| Insani et al. | Honey as a treatment for diabetic foot ulcer: a systematic review | |
| Zhou et al. | Use of mechanical stretching to treat skin graft contracture | |
| CN109045357B (en) | Provenance skin and preparation method thereof | |
| Fatemi et al. | Treatment of third-degree burn wounds in animal specimens: acellular dermis or partial-thickness skin graft | |
| RU2553376C2 (en) | Method of burn wounds treatment | |
| CN103495041A (en) | Qi-tonifying blood-activating drink for treating Alzheimer disease | |
| Badis et al. | Comparative study of the therapeutic efficacy of autologous platelet-rich plasma and honey in healing skin wounds in sheep | |
| CN102552880A (en) | Biological preparation for promoting skin wound to be healed | |
| CN103007260A (en) | Preparation method of medicine for rapidly healing burned tissue | |
| DE112019002479B4 (en) | METHOD OF MANUFACTURING A COLLAGEN-LAMININE MATRIX FOR THE HEALING OF SKIN ULASTERS, BURNS AND WOUNDS IN HUMANS | |
| Fekry et al. | Improvement of hair transplantation in postcicatracial alopecia | |
| US20220079999A1 (en) | Antivenom compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |